KeifeRx Announces Research Collaboration and Option Agreement with Amneal Pharmaceuticals to Advance KFRX06, a Brain-Penetrant LRRK2 Program for Parkinson’s Disease
KeifeRx, a privately held biotechnology company developing disease-modifying therapies for neurodegenerative disorders, today announced that it has entered into a research collaboration and option agreement with Amneal Pharmaceuticals to support the pre-IND development of KFRX06, KeifeRx’s preclinical candidate designed to inhibit leucine-rich repeat kinase 2 (LRRK2), a gene strongly implicated in Parkinson’s disease biology.
KeifeRx Announces the Appointments of Dan Feehan and Alison Finger to Board of Directors
KeifeRx, an emerging clinical-stage biopharmaceutical company specializing in the discovery and development of new treatment options for neurodegenerative and immune diseases, announces the appointments of Dan Feehan and Alison Finger to its Board of Directors. Mr. Feehan and Ms. Finger’s diverse expertise and experience enhance KeifeRx’s ability to develop its expanding pipeline of novel kinase inhibitors for the treatment of neurodegenerative, neuroinflammatory, and mast cell-associated diseases.
